Imagine your mother is 78 years old. She takes a small pill each night to help her sleep. She has done this for years. But lately, she has felt unsteady on her feet. She almost fell last week.
This is a common story. Millions of older adults take medications that affect the brain. Doctors call them psychotropic medications. They include sleep aids, anxiety drugs, and some antidepressants. These drugs can help people rest or feel calmer. But they also come with a hidden cost.
They raise the risk of falling.
Falls are a major health problem for people over 65. One in four older adults falls each year. A broken hip or head injury can change a person's life forever. So the question becomes: what if stopping these drugs could prevent those falls?
A new review of 18 studies says it might. But there is a catch. The approach only works when done the right way.
The drug class that raises fall risk
Psychotropic medications work by calming the brain. They slow down nerve signals. This is helpful for anxiety or insomnia. But it also affects balance, reaction time, and coordination.
Think of it like this. Your brain sends signals to your legs to keep you steady. These drugs turn down the volume on those signals. Your feet still work. But the messages from your brain arrive more slowly. That split-second delay can mean the difference between catching yourself and falling.
Doctors have known about this risk for years. But stopping these drugs is not simple. Many older adults have taken them for a long time. They worry about withdrawal or losing sleep. Their doctors worry about causing other problems.
Researchers looked at 18 studies involving older adults in different settings. Some people lived at home. Others were in hospitals or nursing homes. All were 65 or older.
The researchers wanted to know one thing. Does a structured plan to stop or reduce psychotropic medications lead to fewer falls?
The answer depends on where you are and how well the plan is followed.
In hospitals, the results were clear. Patients who had their psychotropic medications reduced or stopped fell 57 percent less often. That is a large drop. For every 100 patients who got this care, about 10 fewer people fell.
For people living at home, the picture was more mixed. On average, stopping these drugs did not significantly reduce falls. But when researchers looked closer, they found something important.
The programs that followed a strict, careful plan cut fall risk by 39 percent.
Programs that were less structured showed no benefit. This tells us that the method matters as much as the goal.
Why some programs worked better
High-fidelity is a fancy term. It just means the program was followed exactly as designed. These programs included regular check-ins. They had clear steps for tapering off medications slowly. They involved the patient's primary doctor and often a pharmacist.
Low-fidelity programs were looser. A doctor might suggest stopping a drug. But there was no follow-up. No one checked if the patient actually stopped. No one managed withdrawal symptoms.
This difference makes sense. Stopping a sleep aid after years of use is hard. People may have trouble sleeping for weeks. Without support, they often go back on the drug. The fall risk returns.
What this means for you or your parents
If you are 65 or older and take a sleep aid or anxiety medication, do not stop it on your own. That can be dangerous. Withdrawal from some of these drugs can cause seizures, confusion, or severe anxiety.
Instead, talk to your doctor. Ask if a structured deprescribing program is right for you. This means a plan to slowly reduce your dose over weeks or months. It includes monitoring and support.
The research shows that this approach works best in hospitals right now. For people at home, the evidence is promising but not yet proven for everyone. More studies are needed.
The honest limitations
This review has limits. Most of the studies were small. The quality of the evidence was low to very low. That means we cannot be certain the results will hold up in larger studies.
Also, the hospital results came from nonrandomized studies. These are less reliable than randomized trials. The people who got the deprescribing program may have been different from those who did not.
And the review did not look at long-term outcomes. We do not know if the benefits last for months or years.
What happens next
Researchers are planning larger trials. They want to test these programs in more settings. They want to see which patients benefit most. They also want to find the best way to help people stop these medications safely.
For now, the message is clear. Deprescribing psychotropic medications can reduce falls. But it requires a careful, structured approach. A quick suggestion from a doctor is not enough. Patients need support, monitoring, and time.
If you or someone you love takes these medications, have the conversation. Ask about a deprescribing plan. It might just prevent a fall that changes everything.